DDW

US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch

Retrieved on: 
水曜日, 6月 12, 2024
Launch, RealTime, Ulcerative colitis, DDW, Benchmarking, AbbVie, Gastroenterology, HCP, Pharmaceutical industry

While Eli Lilly’s Omvoh, another IL-23 inhibitor, was approved in late 2023, over one-third of gastroenterologists maintain that Skyrizi is a significant advance over existing UC treatments.

Key Points: 
  • While Eli Lilly’s Omvoh, another IL-23 inhibitor, was approved in late 2023, over one-third of gastroenterologists maintain that Skyrizi is a significant advance over existing UC treatments.
  • Further, most gastroenterologists indicate that they are highly familiar with Skyrizi, consistent with their experience using the brand in Crohn’s disease (CD) since June of 2022.
  • Compared to Johnson and Johnson’s Tremfya (guselkumab) and Abivax’s obefazimod, a clear majority of gastroenterologists chose Skyrizi as their preferred agent in development.
  • Furthermore, once Skyrizi is approved in UC, the overwhelming majority of gastroenterologists expect to prescribe the product within the first six months.

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Retrieved on: 
月曜日, 6月 10, 2024
University of Alabama, Eos, Division, Patient, University, National Cancer Institute, Atrophic gastritis, Doctor of Philosophy, Atrophy, Hepatology, Clinical study design, Vanderbilt University Medical Center, Therapy, Efficacy, DDW, DNA, Cancer, MSN, Safety, Histology, Polyamine, Aes, Stomach, EOT, Survival, DFMO, Endoscopy, DNA repair, OTCQB, PBLA, Pharmaceutical industry

MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21, 2024.

Key Points: 
  • MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21, 2024.
  • “Gastric adenocarcinoma is the fifth leading global cause of cancer mortality and leading infection-associated cancer.
  • In the U.S., gastric adenocarcinoma represents a major cancer disparity, with incidence rates 2-3 times or more greater in all non-white populations.
  • At baseline, 80% of subjects were Hp positive, and 46% and 54% had global histology of atrophy and intestinal metaplasia, respectively.

CinRx Pharma Announces Additional $73 Million Financing

Retrieved on: 
木曜日, 5月 30, 2024
Biotechnology, Pharmaceutical, Health, DDW, Patient, Diarrhea, Investigational New Drug, Gastroparesis, Collection, PYY, Obesity, Deudomperidone, IND, Drug development, Safety, Conference, IBS-D, Janssen Pharmaceuticals, Domperidone, Hypertension, IPO, Acquisition, Body composition, Roche, QT, Cinergy, AstraZeneca, Phloroglucinol, Pharmaceutical industry

CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.

Key Points: 
  • CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.
  • In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies.
  • In early 2023, CinCor was acquired by AstraZeneca in a deal worth $1.3 billion upfront and an additional $500 million in biobucks.
  • CinDome recently raised $40 million in a Series B financing from Perceptive Advisors and CinRx, and is actively enrolling the Phase 2 envision3D study for adults with diabetic gastroparesis, expected to read out in 2025.

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Retrieved on: 
水曜日, 5月 22, 2024
Oral medicine, Patient, Immunoglobulin E, DDW, Lung, Doctor of Philosophy, American Thoracic Society, Cytokine, Eosinophilic esophagitis, Dupilumab, Therapy, Histology, Asthma, Phase 1, STAT6, Chemokine, ATS, TPD, Gastrointestinal disease, Inflammation, Resource, HDM, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the presentation of additional preclinical data for KT-621, a potent, selective, oral heterobifunctional degrader of STAT6, at the American Thoracic Society (ATS) Annual Meeting in San Diego, California. The featured data demonstrate activity of KT-621 comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the tested cytokines, chemokines, and cell infiltrates involved in TH2 inflammation in asthma. The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab. These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases. Kymera intends to initiate Phase 1 testing for KT-621 in the second half of 2024 and expects data from the Phase 1 trial to be reported in the first half of 2025.

Key Points: 
  • The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab.
  • These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases.
  • In addition, at low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.
  • Copies of both the ATS and DDW poster presentations are available in the Resource Library section of Kymera's website.

Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Retrieved on: 
火曜日, 5月 21, 2024
DDW, Irritable bowel syndrome, Food, Safety, Constipation, Conference, MD, IBS-C, D.C, Post hoc analysis, Pharmaceutical industry

“We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year’s DDW Conference as we seek to continually elucidate its potential benefit in this patient population.

Key Points: 
  • “We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year’s DDW Conference as we seek to continually elucidate its potential benefit in this patient population.
  • These data provide additional information for both patients and prescribers as they consider IBSRELA as a potential new treatment option when symptoms of IBS-C persist despite current therapies,” said Laura Williams, MD MPH, chief medical officer of Ardelyx.
  • A clinically meaningful response to tenapanor – defined as a complete spontaneous bowel movement response and an abdominal pain response in the same week for ≥6 of the first 12 treatment weeks – was observed among adults with IBS-C regardless of prior IBS-C prescription medication use.
  • Per the analysis, efficacy of tenapanor was comparable, or more pronounced, in Hispanic patients than in non-Hispanic patients.

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells

Retrieved on: 
火曜日, 5月 21, 2024
Physiology, University of Calgary, Therapy, DDW, Doctor of Philosophy, Infection, Cumming School of Medicine, Conditional sentence, University, Movement, GALT, Cell, IVM, Biotechnology, Inflammatory bowel disease, Pharmaceutical industry

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation of new data, using Spinning Disk Intravital Microscopy (IVM), that provides real-time, in vivo visualization of the impact of α4β7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues (GALT). These data were presented in a poster session at Digestive Disease Week (DDW) 2024 meeting.

Key Points: 
  • This real-time footage and the associated data for B cell movement clearly demonstrate that MT-108, a potent and selective small molecule α4β7 inhibitor, leads to increased velocity and flux of rolling lymphocytes.
  • The onset and extent of α4β7 inhibition can be visualized by the increased velocity of B cells when comparing the lymphocyte movement prior to compound administration.
  • In the absence of inhibitor, cells are slowed by their binding of α4β7 with the ligand MAdCAM-1.
  • “These new data demonstrate not only that a small molecule α4β7 inhibitor drives changes comparable to a monoclonal antibody but also provide stunning real time in vivo visualization of this activity.

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

Retrieved on: 
火曜日, 5月 21, 2024
Transfer, IBD, DDW, UC, Colitis, Session, Cytokine, IND, Therapy, MGD, Inflammation, Autoimmunity, VAV1, Ulcerative colitis, Poster, Inflammatory bowel disease, Vaccine

BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at Digestive Disease Week (DDW) 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multiple T-cell and/or Th17 mediated autoimmune and inflammatory diseases, including ulcerative colitis (UC).

Key Points: 
  • The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis.
  • “VAV1 is a well-validated target with significant therapeutic potential in autoimmune and inflammatory diseases but is generally considered undruggable via conventional modalities.
  • These promising preclinical data support our hypothesis that VAV1 is an important target in inflammatory bowel disease (IBD) and also demonstrate MRT-6160's ability to potentially address the underlying disease biology and provide therapeutic benefit,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • MRT-6160 was shown to inhibit disease progression, prevent colon inflammation, and reduce pro-inflammatory cytokine production in a murine T-cell transfer model of colitis.

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Retrieved on: 
火曜日, 5月 21, 2024
Asian literature, IBD, DDW, Disease, Patient, Inflammation, UC, PDE4, Toxicity, DAI, BID, Trial of the century, DSS, AUC, Apremilast, Mouse, Vomiting, Psoriasis, CMO, Internal bleeding, Autoimmunity, Poster, Human body weight, Therapy, Dog, Model, Drinking water, Pharmaceutical industry

The poster is available on the Scientific Publications page of the Company’s website .

Key Points: 
  • The poster is available on the Scientific Publications page of the Company’s website .
  • PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis.
  • Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients.
  • No systemic toxicity in dogs and large therapeutic window due to local activation.

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
月曜日, 5月 20, 2024
Patient, DDW, Inflammation, Doctor of Philosophy, BOCA, Lymphocyte, Clinical trial, Diagnosis, Coeliac disease, Therapy, Health, Conference, Database, Serology, Research, IEL, Poster, Diet, CED, Management

BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.

Key Points: 
  • BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.
  • The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
  • “These findings will enable us to better monitor celiac disease and refine the tools we use in its diagnosis,” said Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics.
  • President & Chief Scientific Officer, Entero Therapeutics; Jennifer Sealy-Voyksner, PhD., Vice President R&D, Entero Therapeutics

Vivante Health Study Finds Digital Digestive Care Supports Health Equity, Presents Findings at Digestive Disease Week 2024

Retrieved on: 
月曜日, 5月 20, 2024
Health, IBD, DDW, Trial of the century, Participation, Digital, Health equity, Research, Happiness, GI, IBS, Gastrointestinal disease, Nursing

CHICAGO, May 20, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for digestive care, today announced the presentation of results from its latest clinical study at Digestive Disease Week® (DDW) 2024.

Key Points: 
  • CHICAGO, May 20, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for digestive care, today announced the presentation of results from its latest clinical study at Digestive Disease Week® (DDW) 2024.
  • Presented by Dr. Hau Liu, Vivante Health's Chief Medical Officer, the findings cover the impact of Vivante Health’s GIThrive program on health outcomes for demographically diverse and socially vulnerable populations.
  • “Digital health interventions can be an excellent way to support vulnerable populations needing access to high-quality specialty care.
  • This study’s exciting findings suggest that virtual digestive disease management is engaging and effective across heterogeneous groups,” said Dr. Bravata.